FDA Physician Labeling Final Rule At OMB
This article was originally published in The Pink Sheet Daily
Executive Summary
"Requirements on Content and Format of Labeling for Human Prescription Drugs and Biological Products" final rule is under review at the Office of Management & Budget. The 2000 proposed rule included a "highlights" section and combined warnings and precautions sections.
You may also be interested in...
FDA Physician Labeling Rule Withdrawn From OMB
Final rule has drawn opposition from industry, especially the addition of a "highlights" section. FDA is proposing staggered implementation to lower the costs of the labeling redesign. Rule would also affect DTC ads. Office of Management & Budget received the reg in January.
FDA Physician Labeling Rule Withdrawn From OMB
Final rule has drawn opposition from industry, especially the addition of a "highlights" section. FDA is proposing staggered implementation to lower the costs of the labeling redesign. Rule would also affect DTC ads. Office of Management & Budget received the reg in January.
New Labeling Rule Will Require Rx Warnings To Appear At Beginning Of DTC Ads
The proposed physician labeling rule will by published by the end of November, FDA Acting Commissioner Crawford says. The rule is designed to provide more useful information to physicians and patients.